KIRKLAND, Wash., Sept. 12, 2019 /PRNewswire/ — Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the publication of the REDUCE FMR clinical study of its Carillon Mitral Contour System®. The Carillon® System is a right heart […]
Other News
V-Wave Receives Second FDA Breakthrough Device Designation: Interatrial Shunt for Pulmonary Arterial Hypertension
CAESAREA, Israel, Sept. 12, 2019 /PRNewswire/ — V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has granted the company a second Breakthrough Device Designation – the first was for its interatrial shunt for Heart Failure (HF), and […]
First Patient Enrolled in Cook Regentec’s Clinical Trial of Investigational Therapy for Critical Limb Ischemia
INDIANAPOLIS–(BUSINESS WIRE)–Cook Regentec today announced enrollment of the first patient in an international clinical trial evaluating the HemaTrate® Blood Filtration System to treat patients with critical limb ischemia (CLI) due to peripheral arterial disease (PAD). To treat CLI, the HemaTrate system produces an autologous, peripheral blood-derived total nucleated cell (TNC) concentrate […]
CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device
CLICHY, France–(BUSINESS WIRE)–CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society for Artificial Organs (ESAO) in Hannover. Trevor Snyder, PhD, Senior Director, Translational and Clinical Research at CorWave, […]
Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure
PARIS and NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in developing a new drug class that a directly targets the brain to treat resistant hypertension and heart failure, today announced that it is launching an additional study with […]
Allina Health becomes first innovation development partner in Excel Medical’s Lighthouse Program
JUPITER, Fla., Sept. 11, 2019 /PRNewswire/ — Excel Medical, an innovator in modernizing cardiac telemetry and medical device integration (MDI), today announced it entered into a collaboration arrangement with Allina Health, as part of the Lighthouse Program. Excel Medical’s Lighthouse Program creates a unique opportunity for health systems to contribute to the design […]
iRhythm Technologies Announces Closing of Follow-on Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SAN FRANCISCO, Sept. 10, 2019 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the closing of its underwritten public offering of 1,575,342 shares of its common stock at a public offering price of $73.00 […]
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
Planned Study Will Assess Effect of Mavacamten on the Need for SRT Among HCM Patients Referred for Invasive Procedures SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy (SRT). The […]
Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark
MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark. The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved […]
Milestone Pharmaceuticals Announces Appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development
MONTREAL and CHARLOTTE, N.C., Sept. 10, 2019 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, today announced the appointment of Amit Hasija as Chief Financial Officer and Executive Vice President of Corporate Development. Mr. Hasija brings to Milestone two decades of […]



